We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · December 08, 2021

NLR as a Prognostic Biomarker in Patients With Advanced RCC Treated With Avelumab Plus Axitinib or Sunitinib

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Association of Neutrophil-to-Lymphocyte Ratio With Efficacy of First-Line Avelumab Plus Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Clin. Cancer Res 2021 Nov 17;[EPub Ahead of Print], MA Bilen, BI Rini, MH Voss, J Larkin, JBAG Haanen, L Albiges, LC Pagliaro, EG Voog, ET Lam, N Kislov, BA McGregor, AA Lalani, B Huang, A di Pietro, S Krulewicz, PB Robbins, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading